WASHINGTON - October 31, 2016 - Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main coronary artery (LMCA) disease, but use of percutaneousa coronary intervention (PCI) for this indication is increasing. Findings from the Nordic-Baltic-British Left Main Revascularization Study (NOBLE) trial found that despite similar mortality, the five-year risk of major adverse events was higher after PCI compared to CABG for the treatment of unprotected LMCA disease.
Findings were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in The Lancet.
The NOBLE trial is a prospective, randomized, open label, clinical, non-inferiority trial that was conducted at 36 sites in Latvia, Estonia, Lithuania, Germany, Norway, Sweden, Finland, United Kingdom and Denmark. Eligible patients had stable angina pectoris, unstable angina pectoris or non-ST elevation myocardial infarction. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCE) - a composite of all-cause mortality, non-procedural myocardial infarction, any repeat coronary revascularization and stroke.
The original primary endpoint was evaluation of non-inferiority of PCI to CABG assessed by MACCE at two years follow-up in the complete study cohort. Due to lower than expected endpoint rates, the primary endpoint assessment was ultimately changed to a median follow-up of three years.
A total of 1,201 patients were randomized 1:1 to PCI (598) or CABG (603), and 592 in each arm entered analysis by intention to treat. Kaplan-Meier five-year estimates of MACCE were 28.9% for PCI (121 events) and 19.1% for CABG (81 events), [HR 1.48 (95% CI 1.11-1.96)], exceeding the limit for non-inferiority and demonstrating superiority of CABG over PCI (P=0.0066). As-treated estimates were 28.1% vs. 19.2% [HR 1.55 (95% CI 1.18-2.04), P=0.0015]. Comparing PCI with CABG, five-year estimates were 11.6% vs. 9.5% [HR 1.07 (95% CI 0.67-1.72), P=0.7701] for all-cause mortality; 6.9% vs. 1.9% [HR 2.88
(95% CI 1.40-5.90), P=0.0040] for non-procedural myocardial infarction; 16.2% vs. 10.4% [HR 1.50 (95% CI 1.04-2.17), P=0.0315] for any revascularization; and 4.9% vs. 1.7% [HR 2.25 (95% CI 0.93-5.48), P=0.0731] for stroke.
"Our findings of similar mortality but higher rates of myocardial infarction and repeat revascularization in patients undergoing PCI compared to CABG are consistent with previous studies of coronary revascularization in patients with LMCA disease," said Evald H. Christiansen, MD, PhD, lead researcher from Aarhus University Hospital, Skejby in Denmark. "However, the low mortality following treatment in both groups demonstrates that modern revascularization techniques can lead to excellent survival in stable LMCA patients. Further, the increased rates of non-procedural myocardial infarction, repeat revascularization and stroke associated with PCI are important considerations in selecting the optimal treatment for individual patients."
The NOBLE trial was funded by Aarhus University Hospital and an institutional research grant from Biosensors. Dr. Christiansen reported receiving institutional grants from Biosensors.
The results of the NOBLE Trial will be presented on Monday, October 31 at 9:15 AM ET in the Main Arena (Ballroom, Level 3) at the Walter E. Washington Convention Center.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.